Document:

Prepared by MerrillDirect

AGREEMENT 

FOR PURCHASE AND SALE OF SHARES OF 

PREFERRED STOCK

OF PEPGEN CORPORATION

             This
Agreement is entered into effective as of April 17, 2001, (the “Effective
Date”), by and between Biotechnology Development Fund I, L.P., a limited
partnership organized under the laws of Delaware (“BDF I”),
Biotechnology Development Fund II, L.P., a limited partnership organized under
the laws of Delaware (“BDF II”), (together the “Purchasers”), and
Calypte Biomedical Corporation (“Seller”), a Delaware corporation.  The principal offices for the Purchasers and
the Seller are shown below each party’s signature at the end of this
Agreement.  Pepgen Corporation (“Pepgen”),
a California corporation with its principal offices at 1255 Harbor Parkway,
Alameda, CA 94502, has executed and delivered this Agreement solely to
acknowledge and consent to the sale of shares of Pepgen effected hereby.

             1.          Purchase and Sale of Shares.  Seller hereby agrees to sell and transfer to
Purchasers, and Purchasers hereby agree to purchase from Seller, the entirety
of Sellers’ shares of Pepgen Series A Preferred Stock (the “Series A Shares”)
and shares of Pepgen Series C Preferred Stock (the “Series C Shares”) in
the amounts listed on the attached Schedule A to this Agreement (collectively
the “Shares”) for an aggregate purchase price of $500,000 (the “Consideration”)
on the relevant closing dates as set forth below in Section 4.

             2.          Assignment of Rights and
Obligations.  Seller hereby
irrevocably assigns, transfers and conveys to the Purchasers all rights and
obligations accorded to Seller (a) by the Master Stock Purchase Agreement dated
September 19, 1995 by and among Pepgen, Seller and the parties listed on the
attached Schedule B to this Agreement (the “Series A Agreement”), (b) by
the Series C Preferred Stock Purchase Agreement dated August 20, 1999 by and
among Pepgen, Seller and the parties listed on the attached Schedule C to this
Agreement (the “Series C Agreement”), and (c) by related principle
documents to the Series C Agreement and by the associated documents listed on
the attached Schedule D to this Agreement. 
Such rights and obligations will be transferred from Sellers to
Purchasers on the relevant closing dates as set forth below in Section 4.

             3.          Notice of Sale.  Seller hereby notifies Pepgen of the
transfer of Shares and all rights and obligations of the Shares’ ownership to
Purchasers pursuant to the terms of this Agreement.

             4.          Closings.

                           (a)         First Closing.. The first
closing of the purchase and sale of the Shares will take place at the offices
of Heller Ehrman White & McAuliffe LLP, 275 Middlefield Road, Menlo Park,
California 94025-3506 at 10:00 a.m. California time, on April 17, 2001 or at
such other time and place as Seller and BDF I ( the “First Closing”)
mutually agree.  At the First Closing,
BDF I shall deliver $171,000 to Seller in the form of a check payable to Seller
or a wire transfer of funds to Seller. 
At the First Closing, Seller shall deliver to BDF I the certificates
representing the number of Shares purchased by BDF I as set forth in Schedule A
together with the following documents: 
(i) the Series A Agreement and related principle financing documents;
(ii) the Series C Agreement and related principle financing documents; and
(iii) documents listed on Schedule D to this Agreement.

                           (b)        Second Closing.  The second closing of the purchase and sale
of the Shares will take place at the offices of Heller Ehrman White &
McAuliffe LLP, 275 Middlefield Road, Menlo Park, California 94025-3506 at 10:00
a.m. California time, on May 1, 2001 or at such other time and place as Seller
and BDF II (the “Second Closing”) mutually agree.  At the Second Closing, BDF II shall deliver
$329,000 to Seller in the form of a check payable to Seller or a wire transfer
of funds to Seller.  Seller shall
deliver to BDF II certificates representing the number of Shares purchased by
BDF II as set forth in Schedule A.

             5.          Pepgen Board of Directors.  Effective as of the Second Closing, Nancy E.
Katz, President, Chief Executive Officer and Chief Financial Officer of Seller,
shall resign her position as the member of Pepgen’s Board of Directors (the “Board”)
who is selected by the holders of a majority of the shares of the Series A
Preferred Stock and the Series B Preferred Stock of Pepgen pursuant to Section
1.1 of the Voting Agreement between Pepgen and the parties listed on Schedule C
to this Agreement (the “Voting Agreement”).

             6.          Voting Agreement.  Pursuant to Section 6.1 of the Voting
Agreement, Purchasers hereby agree to be bound by the terms of the Voting
Agreement.

             7.          Representations and Warranties of
Purchasers.  Purchasers represent
and warrant to Seller, and to Pepgen, that:

                           (a)         Purchase for Own Account for
Investment.  Purchasers are
purchasing the Shares from Seller for Purchasers' own account for investment
purposes only and not with a view to, or for sale in connection with, a
distribution of the Shares within the meaning of the Securities Act of 1933, as
amended (the “1933 Act”). 
Purchasers have no present intention of selling or otherwise disposing
of all or any portion of the Shares and no one other than Purchasers have any
beneficial ownership of any of the Shares.

                           (b)        Access to Information.  Purchasers are “accredited” investors as
defined under Regulation D under the 1933 Act, have had access to all
information regarding Pepgen and Pepgen’s present and prospective business,
assets, liabilities and financial condition that Purchasers reasonably consider
important in making the decision to purchase the Shares, and have had ample opportunity
to ask questions of Pepgen's representatives concerning such matters and this
investment.  Purchasers are not relying
upon any representations or warranties from Seller with respect to the Shares,
except as specifically set forth in Section 3 hereof as to Seller’s authority
to sell, and title to, the Shares, or with respect to Pepgen.

                           (c)         Understanding of Risks.  Purchasers are fully aware of:  (i) the highly speculative nature of the
investment in the Shares; (ii) the financial hazards involved; (iii) the lack
of liquidity of the Shares and the restrictions on transferability of the
Shares (e.g., that Purchasers may not be able to sell or dispose of the
Shares or use them as collateral for loans); (iv) the qualifications and
backgrounds of the management of Pepgen; and (v) the tax consequences of
investment in the Shares.

                           (d)        Purchasers’ Qualifications.  Purchasers have a preexisting personal or
business relationship with Pepgen and/or certain of its officers and/or
directors of a nature and duration sufficient to make Purchasers aware of the
character, business acumen and general business and financial circumstances of
Pepgen and/or such officers and directors. 
By reason of Purchasers’ business or financial experience, Purchasers
are capable of evaluating the merits and risks of this investment, have the
ability to protect Purchasers’ own interests in this transaction and is
financially capable of bearing a total loss of this investment.

                           (e)         No General Solicitation.  At no time were Purchasers presented with or
solicited by any publicly issued or circulated newspaper, mail, radio,
television or other form of general advertising or solicitation in connection
with the offer, sale and purchase of the Shares.

                           (f)         Compliance with Securities Laws.
 Purchasers understand and acknowledge
that, in reliance upon the representations and warranties made by Purchasers
herein, the Shares are not being registered with the Securities and Exchange
Commission (“SEC”) nor are they being qualified under the California
Corporate Securities Law of 1968, as amended or the laws of any other state,
but instead are being issued under an exemption or exemptions from the
registration and qualification requirements of relevant law, which impose
certain restrictions on Purchasers’ ability to transfer the Shares.

                           (g)        Restrictions on Transfer.  Purchasers understand that any subsequent
transfer by the Purchasers of some or all of the Series A Shares and/or the
Series C Shares are subject to limitations set forth in Section 4.5 of the
Series C Agreement and that the subsequent transfer of certain rights and
obligations associated with ownership of the Shares may be subject to further
conditions and limitations set forth in the Voting Agreement and in the
Information and Registration Rights Agreement between Pepgen and the parties
listed on Schedule C to this Agreement.

                           (h)        Rule 144.  Purchasers understand that SEC Rule 144
promulgated under the 1933 Act, which permits certain limited sales of
unregistered securities, is not presently available with respect to the Shares
and, in any event, requires that the Shares be held for a minimum period, after
they have been purchased and paid for (within the meaning of Rule 144), before
they may be resold under Rule 144. 
Purchasers understand that Rule 144 may indefinitely restrict transfer
of the Shares if Purchasers are, and for so long as Purchasers remain,
“affiliates” of Pepgen and “current public information” about Pepgen (as
defined in Rule 144) is not publicly available.

                           (i)          Legends and Stop-Transfer Orders.  Purchasers understand that certificates or
other instruments representing any of the Shares acquired by Purchasers will
bear legends required by federal or state laws or by the Bylaws of Pepgen or
under any agreements to which the Shares are subject and which would impose
legend obligations on the Shares as transferred hereby.  Purchasers agree that, in order to ensure
and enforce compliance with the restrictions imposed by applicable law and
those referred to in the foregoing legends, or elsewhere herein, Pepgen may
issue appropriate “stop transfer” instructions to its transfer agent, if any,
with respect to any certificate or other instrument representing the Shares, or
if Pepgen transfers its own securities, that it may make appropriate notations
to the same effect in Pepgen's records.

                           (j)          Rights and Obligations Applicable
to the Shares as Sold; Execution and Delivery of Additional Documents as
Condition to Sale.  Purchasers have
made their own investigation of any restrictions imposed upon, or rights
applicable to, the Shares, or upon or for the benefit of Purchasers as the
holders thereof, by law or by any written agreement applicable to the Shares as
held by Purchasers as transferees from Seller, and Purchasers have executed and
delivered all instruments and documents and otherwise complied with all
obligations required, as of the Effective Date, to be complied with by
Purchasers under written agreements applicable to the Shares and to this
transfer and sale to Purchasers.

             8.          Representations
and Warranties By Seller.  Seller
represents and warrants to Purchasers that:

                           (a)         Seller has full authority and power to
execute and deliver this Agreement and, subject in part to the truthfulness of
Purchasers’ representations herein, to sell and transfer the Shares to
Purchasers as provided herein.  This
Agreement has been duly executed and delivered by Seller and constitutes the
valid and binding obligation of Seller enforceable against Seller in accordance
with its respective terms.

                           (b)        Seller is the sole and exclusive owner,
beneficially and of record, of all the Shares, free and clear of all liens,
encumbrances, security agreements, pledges, preemptive rights, options,
proxies, claims and charges.  Upon each
of the First Closing and the Second Closing, and the delivery of the
certificates representing the Shares pursuant to this Agreement, Seller will
transfer to Purchasers good and valid title to the Shares and such Shares shall
be free and clear of any liens, adverse claims, encumbrances or agreements,
preemptive rights, co-sale rights, rights of refusal, repurchase rights, voting
trusts and other restrictions of any kind.

                           (c)         Seller has held the Shares continuously
since the date such Shares were issued by Pepgen.

                           (d)        Seller is not aware that the initial
issuance and sale of the Shares to Seller by Pepgen was not in compliance with
all applicable federal and State of California securities laws.

                           (e)         At no time did Sellers present or
solicit by means of any publicly issued or circulated newspaper, mail, radio,
television or other form of general advertising or solicitation in connection
with the offer, sale and purchase of the Shares.

                           (f)         The execution, delivery of this
Agreement and the performance of its respective terms will not, with or without
the giving of notice or the passage of time, conflict with, constitute a
violation or breach of or result in a default under, result in the acceleration
of, create in any party the right to accelerate, terminate, modify, or cancel
or require any notice or consent under (a) any contract, lease, license,
franchise, permit, indenture, agreement or mortgage for borrowed money,
instrument of indebtedness, security interest, or other arrangement to which
Seller is a party or by which Seller is bound or to which any of Seller’s
assets are subject, (b) any order, writ, injunction, award, decree,
decision or ruling of any court, arbitrator or governmental or regulatory body
against or binding Seller, or (c) any statute, law, rule or regulation of
any jurisdiction to which Seller may be subject.

                           (g)        Subject in part to the truth and accuracy of the
Purchasers’ representations set forth in Section 5, the offer, sale and
transfer of the Shares as contemplated by this Agreement is exempt from the
registration requirements of the Securities Act of 1933, as amended (the “Act”)
and from the registration and qualification requirements of applicable state
securities laws, and neither the Seller, nor any authorized agent acting on its
behalf, will take any action hereafter that would cause the loss of such
exemptions.

             9.          Legal
Fees.  Seller shall reimburse the
Purchasers for legal fees incurred by the Purchasers in connection with this
transaction in an amount not to exceed $5,000.

             10.        Further
Assurances.  Seller agrees, at its
sole cost and expense, to assist Purchasers to effectuate the purposes and
intent of this Agreement and shall cooperate with Purchasers to effectuate the
transfer of the record title to the Shares on the books and records of Pepgen
from Seller to Purchasers

             11.        General.  This Agreement may be executed in
counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument.  This Agreement will be governed by the laws of the State of
California without regard to its body of law controlling conflict of laws.  This Agreement is the complete and exclusive
agreement of the parties hereto regarding the specific subject matter of this Agreement
and supersedes in their entirety all prior agreements, understandings and
communications, oral or written, between or among the parties regarding the
specific subject matter of this Agreement, will be binding upon and inure to
the parties’ respective successors and assigns, and may only be amended by a
writing signed by the parties hereto or their respective successors, assigns or
authorized representatives.

Rest of Page Left Intentionally
Blank

IN
WITNESS WHEREOF, the parties have executed and delivered this Agreement as of
the Effective Date.

	SELLER:	 	 	PURCHASERS:	 
	 	 	 	 	 	 
	CALYPTE BIOMEDICAL
  CORPORATION	 	BIOTECHNOLOGY
  DEVELOPMENT FUND I, L.P
	 	 	 	 	 	 
	By:	/s/  Nancy E. Katz	 	By:	BioAsia Investments,
  LLC, General Partner	 
	 	

	 	 	 	 
	Name:	Nancy E. Katz	 	 	 	 
	Title:	Chief Executive
  Officer, President and Chief	 	By:	/s/  Frank Kung	 
	 	Financial Officer	 	 	

	 
	 	 	 	Name:	Frank Kung	 
	 	 	 	Title:	Managing Member	 
	 	 	 	 	 	 
	Address:	1265 Harbor Bay
  Parkway, Alameda,	 	 	 	 
	 	California  94502	 	Address:	575 High Street, Suite
  201, Palo Alto,	 
	 	 	 	 	California  94301	 
	 	 	 	 	 	 
	 	 	 	BIOTECHNOLOGY
  DEVELOPMENT FUND II, L.P.	 
	 	 	 	 	 
	 	 	 	By:	BioAsia Management,
  LLC, General Partner	 
	 	 	 	 	 	 
	 	 	 	By:	/s/  Frank Kung	 
	 	 	 	 	

	 
	 	 	 	Name:	Frank Kung	 
	 	 	 	Title:	Managing Member	 
	 	 	 	 	 	 
	 	 	 	Address:	575 High Street, Suite
  201, Palo Alto,	 
	 	 	 	 	California  94301	 
	 	 	 	 	 	 
								

 

ACKNOWLEDGED
AND SALE OF SHARES CONSENTED TO:

	PEPGEN CORPORATION
	 	 
	By:	/s/  C. P. Liu
	 	

	 	 
	Name:	C. P. Liu
	 	

	 	 
	Title:	PresidentPrepared by MerrillDirect

Exhibit
10.A

AMENDMENT
NO. 1

TO

EMPLOYMENT AGREEMENT

 

             THIS
AMENDMENT NO. 1 (the “Amendment No. 1”) is entered into as of June
30, 2001, and amends the Employment Agreement, dated February 18, 2000, by and
among Voice and Wireless Corporation, a Minnesota corporation f/k/a Kensington
International Holding Corporation (the “Company”), Mail Call, Inc., a Florida
corporation (“Mail Call”), and Ronald Schnell (“Employee”) (the
"Agreement").  Defined terms herein shall have the meaning
ascribed to them in the Agreement unless defined herein.

AGREEMENT

             NOW,
THEREFORE,in consideration of the mutual covenants and
conditions set forth herein, and other good and valuable consideration the
receipt and sufficiency of which are hereby acknowledged, the parties hereto do
hereby agree as follows:

             1.          Paragraph 1 of the Agreement is hereby
amended and restated in its entirety to read as follows:

1.          Employment.  The Employee is to be employed in the
capacity of Vice President of the Company and Vice President of Mail Call, and
shall perform the duties customarily performed by persons situated in a similar
capacity.  The Employee’s other duties
shall be such as the Company's President or the Company's Board of Directors
(the “Board of Directors” or “Board”) may from time to time reasonably
direct.  The Employee agrees that should
Mail Call be merged into the Company, the Employee shall continue as the Vice
President of the Company.  The Employee
agrees that as Vice President, his duties do not include any sales, marketing
or administrative duties, unless specifically assigned by the Company's Chief
Executive Officer or President.  The
Employee further agrees that he shall work full-time for the Company on
technical services and on enhancing technical services for the Company as
directed by the Company's President. 
The Employee further agrees to train other employees of the Company on
technical aspects of Mail Call and the Company, and agrees to oversee the
technical employees of the Company and Mail Call.

             2.          Except
for the provisions expressly amended pursuant to the terms of this Amendment
No. 1, all of the remaining terms and conditions of the Agreement remain in
full force and effect and are unaffected by the execution of this Amendment No.
1.

             3.          This
Amendment No. 1 may be executed in any number of counterparts and by the
several parties hereto in separate counterparts, each of which shall be deemed
to be an original and all of which together shall be deemed to be one and the
same instrument.

             IN WITNESS WHEREOF, the undersigned
have executed this Amendment No. 1 as of the date first written above.

	 	VOICE AND WIRELESS CORPORATION
	 	 	 
	 	By:	 
	 	 	

	 	 	Mark Haggerty
	 	 	President and Chief Executive Officer
	 	 	 
	 	MAIL CALL, INC.
	 	 	 
	 	By:	 
	 	 	

	 	 	Mark Haggerty
	 	 	President
	 	 	 
	 	 	 
	 	

	 	Ronald Schnell, Individually

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]